Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen
Stefan Peinert(Peter MacCallum Cancer Centre), Dirk Hönemann(Peter MacCallum Cancer Centre), H. Miles Prince(Monash University), Joseph A. Trapani(University of Melbourne), Paul J. Neeson(The University of Melbourne), Phillip K. Darcy(The University of Melbourne), Kellie M. Tainton(Peter MacCallum Cancer Centre), Mark J. Smyth(The University of Queensland), Andrew M. Scott(Ludwig Cancer Research), David Ritchie(Peter MacCallum Cancer Centre), P Guru(Peter MacCallum Cancer Centre), Simon J. Harrison(The University of Melbourne), Peter Gambell(Peter MacCallum Cancer Centre), Fiona E. Smyth(Ludwig Cancer Research), Michael H. Kershaw(Peter MacCallum Cancer Centre)
Cited by 118
Related Papers
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639